Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA approves human trial using biomaterials for spinal cord injury.
Abstract
The article reports on the U.S. Food and Drug Administration's (FDA) approval of InVivo Therapeutics Holdings Corp.'s investigational device exemption (IDE) to start human studies that will test a biopolymer scaffold product to treat patients with acute, traumatic spinal cord injury (SCI).